Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

"Wisest Is He Who Knows What He Does Not Know."

Marks LB, Tepper JE.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):687-690. doi: 10.1016/j.ijrobp.2018.01.009. Epub 2018 Oct 18. No abstract available.

PMID:
30353877
2.

Organ-specific metastases obtained by culturing colorectal cancer cells on tissue-specific decellularized scaffolds.

Tian X, Werner ME, Roche KC, Hanson AD, Foote HP, Yu SK, Warner SB, Copp JA, Lara H, Wauthier EL, Caster JM, Herring LE, Zhang L, Tepper JE, Hsu DS, Zhang T, Reid LM, Wang AZ.

Nat Biomed Eng. 2018;2:443-452. Epub 2018 Apr 23.

3.

Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.

Chera BS, Amdur RJ, Tepper JE, Tan X, Weiss J, Grilley-Olson JE, Hayes DN, Zanation A, Hackman TG, Patel S, Sheets N, Weissler MC, Mendenhall WM.

Cancer. 2018 Jun 1;124(11):2347-2354. doi: 10.1002/cncr.31338. Epub 2018 Mar 26.

PMID:
29579339
4.

Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture.

Myung JH, Eblan MJ, Caster JM, Park SJ, Poellmann MJ, Wang K, Tam KA, Miller SM, Shen C, Chen RC, Zhang T, Tepper JE, Chera BS, Wang AZ, Hong S.

Clin Cancer Res. 2018 Jun 1;24(11):2539-2547. doi: 10.1158/1078-0432.CCR-17-3078. Epub 2018 Mar 15.

PMID:
29545463
5.

A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy.

Moon DH, Wang AZ, Tepper JE.

Radiother Oncol. 2018 Mar;126(3):527-533. doi: 10.1016/j.radonc.2018.01.004. Epub 2018 Jan 30.

PMID:
29366521
6.

Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).

Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ.

J Clin Oncol. 2017 Nov 10;35(32):3671-3677. doi: 10.1200/JCO.2017.74.2130. Epub 2017 Oct 4.

7.

Oncologist, cancer patient, oncologist.

Tepper JE.

Pract Radiat Oncol. 2018 Sep - Oct;8(5):295-296. doi: 10.1016/j.prro.2017.08.007. Epub 2017 Aug 31. No abstract available.

PMID:
28943260
8.

Ethics in Clinical Care.

Tepper JE.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):250-254. doi: 10.1016/j.ijrobp.2017.03.036. Epub 2017 Mar 29. No abstract available.

PMID:
28871965
9.

Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.

Min Y, Roche KC, Tian S, Eblan MJ, McKinnon KP, Caster JM, Chai S, Herring LE, Zhang L, Zhang T, DeSimone JM, Tepper JE, Vincent BG, Serody JS, Wang AZ.

Nat Nanotechnol. 2017 Sep;12(9):877-882. doi: 10.1038/nnano.2017.113. Epub 2017 Jun 26.

10.

Introduction.

Koong AC, Tepper JE.

Semin Radiat Oncol. 2017 Jul;27(3):189. doi: 10.1016/j.semradonc.2017.03.005. Epub 2017 Mar 18. No abstract available.

PMID:
28577825
11.

CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α.

Tian X, Nguyen M, Foote HP, Caster JM, Roche KC, Peters CG, Wu P, Jayaraman L, Garmey EG, Tepper JE, Eliasof S, Wang AZ.

Cancer Res. 2017 Jan 1;77(1):112-122. doi: 10.1158/0008-5472.CAN-15-2951. Epub 2016 Oct 26. Erratum in: Cancer Res. 2017 Dec 1;77(23 ):6790-6791.

12.

Special Series: Advances in GI Cancer.

Meyerhardt JA, Tepper JE, Venook AP.

J Clin Oncol. 2015 Jun 1;33(16):1717-20. doi: 10.1200/JCO.2015.60.8661. Epub 2015 Apr 27. No abstract available.

PMID:
25918284
13.

Local iontophoretic administration of cytotoxic therapies to solid tumors.

Byrne JD, Jajja MR, O'Neill AT, Bickford LR, Keeler AW, Hyder N, Wagner K, Deal A, Little RE, Moffitt RA, Stack C, Nelson M, Brooks CR, Lee W, Luft JC, Napier ME, Darr D, Anders CK, Stack R, Tepper JE, Wang AZ, Zamboni WC, Yeh JJ, DeSimone JM.

Sci Transl Med. 2015 Feb 4;7(273):273ra14. doi: 10.1126/scitranslmed.3009951.

14.

Scoring the recurrence score in rectal cancer.

Tepper JE, Wang AZ.

J Natl Cancer Inst. 2014 Sep 26;106(11). pii: dju295. doi: 10.1093/jnci/dju295. Print 2014 Nov. No abstract available.

PMID:
25261969
15.

Radiation oncology: a snapshot in time, 2014.

Kavanagh BD, Haffty BG, Tepper JE.

J Clin Oncol. 2014 Sep 10;32(26):2825-6. doi: 10.1200/JCO.2014.57.3071. Epub 2014 Aug 11. No abstract available.

16.

Nanotechnology in radiation oncology.

Wang AZ, Tepper JE.

J Clin Oncol. 2014 Sep 10;32(26):2879-85. doi: 10.1200/JCO.2014.55.0699. Epub 2014 Aug 11. Review.

17.

Reply to E. C. Smyth et al.

Mamon HJ, Tepper JE.

J Clin Oncol. 2014 Sep 20;32(27):3082. doi: 10.1200/JCO.2014.56.3874. Epub 2014 Jul 28. No abstract available.

PMID:
25071102
18.

Colorectal cancer: all hands on deck.

Venook AP, Weiser MR, Tepper JE.

Am Soc Clin Oncol Educ Book. 2014:83-9. doi: 10.14694/EdBook_AM.2014.34.83. Review.

19.

Combination chemoradiation therapy: the whole is more than the sum of the parts.

Mamon HJ, Tepper JE.

J Clin Oncol. 2014 Feb 10;32(5):367-9. doi: 10.1200/JCO.2013.54.3108. Epub 2014 Jan 13. No abstract available.

PMID:
24419110
20.

Practice patterns and long-term survival for early-stage rectal cancer.

Stitzenberg KB, Sanoff HK, Penn DC, Meyers MO, Tepper JE.

J Clin Oncol. 2013 Dec 1;31(34):4276-82. doi: 10.1200/JCO.2013.49.1860. Epub 2013 Oct 28.

21.

Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future?

Snyder A, Tepper JE, Slovin SF.

Semin Oncol. 2013 Jun;40(3):347-60. doi: 10.1053/j.seminoncol.2013.04.009. Review.

PMID:
23806499
22.

Intraoperative electron radiation therapy as an important treatment modality in retroperitoneal sarcoma.

Sweeting RS, Deal AM, Llaguna OH, Bednarski BK, Meyers MO, Yeh JJ, Calvo BF, Tepper JE, Kim HJ.

J Surg Res. 2013 Nov;185(1):245-9. doi: 10.1016/j.jss.2013.05.015. Epub 2013 May 29.

23.

Applicability of randomized trials in radiation oncology to standard clinical practice.

Apisarnthanarax S, Swisher-McClure S, Chiu WK, Kimple RJ, Harris SL, Morris DE, Tepper JE.

Cancer. 2013 Aug 15;119(16):3092-9. doi: 10.1002/cncr.28149. Epub 2013 May 14.

24.

Gastrointestinal cancers and the cooperative groups-2011.

Tepper JE.

Gastrointest Cancer Res. 2012 May;5(3 Suppl 1):S1-3.

25.

Wound complications in preoperatively irradiated soft-tissue sarcomas of the extremities.

Rosenberg LA, Esther RJ, Erfanian K, Green R, Kim HJ, Sweeting R, Tepper JE.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):432-7. doi: 10.1016/j.ijrobp.2012.04.037. Epub 2012 Jun 5.

26.

A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.

Raftery L, Tepper JE, Goldberg RM, Blackstock AW, Aklilu M, Bernard SA, Ivanova A, Davies JM, O'Neil BH.

Am J Clin Oncol. 2013 Jun;36(3):250-3. doi: 10.1097/COC.0b013e3182467f22.

27.

Concomitant radiotherapy and chemotherapy for high-risk nonmelanoma skin carcinomas of the head and neck.

Apisarnthanarax S, Dhruva N, Ardeshirpour F, Tepper JE, Shores CG, Rosenman JG, Shockley WW, Hayward MC, Hayes DN.

Int J Surg Oncol. 2011;2011:464829. doi: 10.1155/2011/464829. Epub 2011 Sep 25.

28.

Minimizing therapy and maximizing outcomes in rectal cancer.

Tepper JE, O'Neil BH.

J Clin Oncol. 2011 Dec 10;29(35):4604-6. doi: 10.1200/JCO.2011.38.1335. Epub 2011 Nov 7. No abstract available.

PMID:
22067395
29.

Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy.

Davies JM, Trembath D, Deal AM, Funkhouser WK, Calvo BF, Finnegan T, Weck KE, Tepper JE, O'Neil BH.

Radiat Oncol. 2011 Sep 12;6:114. doi: 10.1186/1748-717X-6-114.

30.

A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.

Mamon HJ, Niedzwiecki D, Hollis D, Tan BR, Mayer RJ, Tepper JE, Goldberg RM, Blackstock AW, Fuchs CS; Cancer and Leukemia Group B.

Cancer. 2011 Jun 15;117(12):2620-8. doi: 10.1002/cncr.25742. Epub 2010 Dec 23.

31.

Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.

Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC.

J Clin Oncol. 2011 Mar 1;29(7):934-43. doi: 10.1200/JCO.2010.33.2056. Epub 2011 Jan 24.

32.

Technology evolution: is it survival of the fittest?

Zietman A, Goitein M, Tepper JE.

J Clin Oncol. 2010 Sep 20;28(27):4275-9. doi: 10.1200/JCO.2010.29.4645. Epub 2010 Aug 9.

PMID:
20697074
33.

Nuclear factor κ-light chain-enhancer of activated B cells is activated by radiotherapy and is prognostic for overall survival in patients with rectal cancer treated with preoperative fluorouracil-based chemoradiotheraphy.

O'Neil BH, Funkhouser WK, Calvo BF, Meyers MO, Kim HJ, Goldberg RM, Bernard SA, Caskey L, Deal AM, Wright F, Baldwin AS, Tepper JE.

Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):705-11. doi: 10.1016/j.ijrobp.2010.02.063. Epub 2010 Jul 12.

34.

NF-kB and Bcl-3 activation are prognostic in metastatic colorectal cancer.

Puvvada SD, Funkhouser WK, Greene K, Deal A, Chu H, Baldwin AS, Tepper JE, O'Neil BH.

Oncology. 2010;78(3-4):181-8. doi: 10.1159/000313697. Epub 2010 Apr 23.

35.

Clinical medicine and clinical trials.

Tepper JE.

Oncologist. 2010;15(4):382-7. doi: 10.1634/theoncologist.2009-S107. No abstract available.

36.

A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer.

O'Neil BH, Raftery L, Calvo BF, Chakravarthy AB, Ivanova A, Myers MO, Kim HJ, Chan E, Wise PE, Caskey LS, Bernard SA, Sanoff HK, Goldberg RM, Tepper JE.

Clin Colorectal Cancer. 2010 Apr;9(2):119-25. doi: 10.3816/CCC.2010.n.017.

37.

Improving local control in rectal cancer: radiation sensitizers or radiation dose?

Tepper JE, Wang AZ.

J Clin Oncol. 2010 Apr 1;28(10):1623-4. doi: 10.1200/JCO.2009.26.9787. Epub 2010 Mar 1. No abstract available.

PMID:
20194836
38.

The landscape of somatic copy-number alteration across human cancers.

Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M.

Nature. 2010 Feb 18;463(7283):899-905. doi: 10.1038/nature08822.

39.

Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.

Kimple RJ, Vaseva AV, Cox AD, Baerman KM, Calvo BF, Tepper JE, Shields JM, Sartor CI.

Clin Cancer Res. 2010 Feb 1;16(3):912-23. doi: 10.1158/1078-0432.CCR-09-1324. Epub 2010 Jan 26.

40.

Randomized trials and technology assessment.

Tepper JE, Blackstock AW.

Ann Intern Med. 2009 Oct 20;151(8):583-4. Epub 2009 Sep 14. No abstract available.

PMID:
19755346
41.

The impact of the privacy rule on cancer research: variations in attitudes and application of regulatory standards.

Goss E, Link MP, Bruinooge SS, Lawrence TS, Tepper JE, Runowicz CD, Schilsky RL.

J Clin Oncol. 2009 Aug 20;27(24):4014-20. doi: 10.1200/JCO.2009.22.3289. Epub 2009 Jul 20.

PMID:
19620480
42.

Biomarkers for response to neoadjuvant chemoradiation for rectal cancer.

Kuremsky JG, Tepper JE, McLeod HL.

Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):673-88. doi: 10.1016/j.ijrobp.2009.03.003. Review.

PMID:
19480968
43.
44.

Crossroads in the combined-modality management of gastroesophageal junction carcinomas.

Apisarnthanarax S, Tepper JE.

Gastrointest Cancer Res. 2008 Sep;2(5):235-43.

45.

Transition in biology and philosophy in the treatment of gastroesophageal junction adenocarcinoma.

Tepper JE, O'Neil B.

J Clin Oncol. 2009 Feb 20;27(6):836-7. doi: 10.1200/JCO.2008.19.5982. Epub 2009 Jan 12. No abstract available.

PMID:
19139425
46.

Protons and parachutes.

Tepper JE.

J Clin Oncol. 2008 May 20;26(15):2436-7. doi: 10.1200/JCO.2008.17.1165. Epub 2008 Apr 28. No abstract available.

PMID:
18443346
47.

Diabetes mellitus affects response to neoadjuvant chemoradiotherapy in the management of rectal cancer.

Caudle AS, Kim HJ, Tepper JE, O'Neil BH, Lange LA, Goldberg RM, Bernard SA, Calvo BF, Meyers MO.

Ann Surg Oncol. 2008 Jul;15(7):1931-6. doi: 10.1245/s10434-008-9873-6. Epub 2008 Apr 17.

PMID:
18418656
48.

Current options for the management of rectal cancer.

O'Neil BH, Tepper JE.

Curr Treat Options Oncol. 2007 Oct;8(5):331-8. doi: 10.1007/s11864-007-0048-7. Review.

PMID:
18181024
49.

Rectal cancer radiotherapy.

Ramsey S, Tepper JE.

Cancer J. 2007 May-Jun;13(3):204-9. Review.

PMID:
17620771
50.

Postoperative irradiation for rectal cancer increases the risk of small bowel obstruction after surgery.

Baxter NN, Hartman LK, Tepper JE, Ricciardi R, Durham SB, Virnig BA.

Ann Surg. 2007 Apr;245(4):553-9.

Supplemental Content

Loading ...
Support Center